Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Similar documents
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

CHEMOTHERAPY


VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

CHEMOTHERAPY

Fig.1 Chemical structure of BAY o 9867

CHEMOTHERAPY

1272 CHEMOTHERAPY MAR. 1975


Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

Fig. 1 Chemical structure of DL-8280

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates


Table1MIC of BAY o 9867 against standard strains

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

日本化学療法学会雑誌第61巻第6号

CHEMO THE RAPY OCT. 1994

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


988 CHEMOTHERAPY NOV. 1971

日本化学療法学会雑誌第64巻第4号


VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.42 S-1



VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study



CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s


- 1 -

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis




VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus


THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

VOL. 43 NO. 4

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

日本化学療法学会雑誌第58巻第4号


Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC


CHEMOTHERAPY MAY. 1988

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

R06_01

日本化学療法学会雑誌第53巻第S-3号

Table 1. Antimicrobial drugs using for MIC

CHEMOTHERAPY JUNE 1986


Acecide_ProductsInformation2010PDF.indd

03-b-„FŒ{›xŒ¾-4.02


VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC


Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)

日本化学療法学会雑誌第55巻第S-1号

HPM_442_F_TgCHG_1128


VOL. 34 S-2 CHEMOTH8RAPY 913

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det


Transcription:

CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Serratia sp., Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa Serratia marcescens, Pseudomonas aeruginosa phylococcus sp., Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Citrobacter P.aeruginosa, Acinetobacter calcoa- Enterobacter sp., Citrobacter sp. freundii, Serratia sp., P.aeruj inosa

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY Table 1. In vitro antibacterial activity of cefclidin against clinical isolates Inoculum size: 106 CFU/ml

VOL.40 S-4 Table 2. Clinical summary of complicated UTI patients treated with cefclidin CCP: chronic complicated pyelonephritis CCC: chronic complicated cystitis VUR: vesicoureteral reflex HAM: HTL V-1 associated myelopathy * before treatment after treatment ** UTI: criteria proposed by the UTI Committee Dr.: Dr's evaluation

CHEMOTHERAPY SEPT. 1992 Table 3. Overall clinical efficacy of cefclidin in complicated UTI Bacteriological response * regardless of bacterial count Table 4. Overall clinical efficacy of cefclidin classified by the type of infection K.pneumoniae, C.freundii, E. cloacae, P. aeruginosa

Table 5. Bacteriological response to cefclidin in complicated UTI *regardless of bacterial count Table 6. Strains*appearing after cefclidin treatment in complicated UTI *regardless of bacterial count YLO: yeast like organism

CHEMOTHERAPY Table 7. Relation between MIC and bacteriological response to cefclidin treatment in complicated UTI No. of strains eradicated/no. of strains isolated Table 8. Changes in laboratory test results 8) Collatz E et al: Developement of resistance to 3) Watanabe N, Katsu K, Moriyama M, and Kitoh K: In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agent Chemother 32: 693 `701, 1988 7) Spratt BG, Pardee AB: Penicillin bin ding protein and cell shape in E.coli. Nature 254: 516,1975 beta-lactam antibiotics with specific referens to third generation cephalosporins. Antimicrob Chemother 14 (B): 13,1984

VOL.40 S-4 9) Yokota T: Methicillin and cephemresistant Staphylococcus aureus. Infect Inflam Immun 14: 87,1984 ANTIMICROBIAL ACTIVITIES AND CLINICAL STUDIES ON CEFCLIDIN IN COMPLICATED URINARY TRACT INFECTION Kazuya Kawahara, Motoshi Kawahara, Yoshihiro Mizuma, Shinichi Makinose Toshihiro Gotou, Nichiro Sakamoto and Yoshitada Ohi Department of Urology, Faculty of Medicine, Kagoshima University 8-35-1, Sakuragaoka, Kagoshima 890, Japan Antimicrobial activities and clinical studies on cefclidin (CFCL), a new injectable cephalosporin, were performed and the following results were obtained. 1. Antibacterial activity of cefclidin Antibacterial activity of CFCL against 10 kinds of urinary pathogenic bacteria consisting of each 30 strains from urine were studied and compared to cefoperazone (CPZ), ceftazidime (CAZ) and imipenem(ipm). As to the antibacterial activities against Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae and Pseudomonas aeruginosa, CFCL was superior to the other drugs. Against Proteus mirabilis and Proteus vulgaris, CFCL showed weaker activities than CAZ, but stronger activities than both IPM and CPZ. Antibacterial activity of CFCL was inferior to CAZ and IPM against Serratia marcescens. 2. Clinical efficacy CFCL was administered in a daily dose of 1.0g or 2.0g for five consecutive days to 15 cases by i. v. or drip infusion. The overall clinical efficacy rate was 86.7% (13/15). 3. Bacteriological response 22 of 23 strains (95.7%) isolated from patients with urinary tract infection including 5 of Grampositive cocci and Gram-negative rods were eradicated. 4. Adverse reaction No severe adverse reactions and abnormal laboratory findings or ophthalmologic disorders was observed.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック